Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02106195 · ClinicalTrials.gov registry record · Phase 2
A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris
A Phase 2 study, sponsored by Kadmon Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02106195: Completed Phase 2 study, sponsored by Kadmon Corporation.
NCT02106195 is a Phase 2 study that has completed, run by Kadmon Corporation. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02106195, a Phase 2 study, has completed, sponsored by Kadmon Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.
Primary Outcome
To evaluate the safety and tolerability of 200 mg of belumosudil administered PO QD to subjects for treatment of psoriasis
Interventions
- DRUG Belumosudil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
What the finished NCT02106195 record still lists
NCT02106195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Belumosudil is the first listed.
NCT02106195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02106195 about?
NCT02106195 is a clinical study titled "A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris". The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.
What is the current status of trial NCT02106195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2014-04. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02106195?
The interventions under investigation include: Belumosudil (DRUG).
Who is sponsoring clinical trial NCT02106195?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02106195's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia